Conclusion and Results:
The patient’s history of anaphylaxis to Rituximab and steroid dependence
post-Tocilizumab complicates the management of her condition,
highlighting the need for alternative therapeutic strategies. It is to
note that she has not experienced any articular pain, which is
strikingly unusual in a known Still’s disease patient. With our patient,
we had no option but to resume steroid therapy, as there is no data on
any other forms of treatment. The patient will also be given a new trial
of rituximab since other treatment options are very limited.